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Studies inanimal tumor models have shownthat localized and disseminated tumors
can be eradicated by the adoptive transfer oftumor-specific syngeneic T cells (1-3).
Analyses oftheeffector T cell subsets participating in tumorrejection have revealed
disparate results in different tumormodels. For example, in vivo generation ofclass
I-restricted tumor-specific CTL hasbeen shown to correlate with rejection ofsome
murine tumors (4-8), while studies utilizing purified populations ofclass II-restricted
tumor-specific Th, capable of inducing delayed-type hypersensitivity (DTH)' re-
sponsesin vivo, have suggested thatnoncytolytic classII-restricted effectors areneces-
saryand sufficient for tumor rejection (9-11). Moreover, in some tumor models both
tumor-specific CTL and Th are required for tumor eradication (3). The disparities
observed in the T cell responses required for tumor eradication in these different
tumor models could reflect unique susceptibility by the tumor toaparticular effector
mechanism. However, most tumors are susceptible to lysis both by CD8+ CTL and
macrophages activated by lymphokines released by CD4+ Th during DTH re-
sponses(12, 13). Therefore, analternativeexplanationfortheseapparent differences
in effector requirements for mediating tumor elimination in some models is that
particular tumors may preferentially induce and/or activate either class I- or class
II-restricted T cell responses.
Presentation ofantigen for activation ofMHC-restricted T cells requires that the
antigen be processed to a peptide that can bind to the appropriate MHC molecule
to form an immunogenic complex. The intracellularprocessingpathwaysthat generate
complexes ofpeptides and MHC antigens are separate for class I and class II mole-
cules (14). Presentation with class II molecules appears torequire that antigen enter
via an exogenouschloroquine-sensitive pathway in which antigen is endocytosedand
degraded in lysozomes (15, 16), whereas presentation with class I molecules appears
to require antigen enter via an endogenous pathway in which proteins produced
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in the cell, rather than endocytosed, are degraded outside lysozomes in the cytoplasm
(17) . Thus, antigens might preferentially interact with one class ofMHC molecule
and/or enter one pathway, resulting in predominant activation of class I- or class
II-restricted T cells .
Previous studies in our laboratory (7, 8, 10, 11) have shown that immunization
ofC57BL/6 (B6) mice with the Friend retrovirus-induced syngeneic leukemia, FBL,
induces both tumor-reactive CD8+ CTL and CD4+ Th, and each is independently
capable ofcompletely rejecting the tumor when transferred as a purified T cell subset
or clone in adoptive therapy of mice bearing disseminated leukemia. Although the
CD4+ Th population can proliferate and mediate its therapeutic DTH effect
without the participation of CD8+ CTL (10, 11), maximal in vitro generation of
FBL-reactive CD8+ CTL and the in vivo therapeutic activity of this subset are de-
pendent on IL-2-producing CD4+ Th or exogenous IL-2 (7, 8, 18) . Activation of
these subsets, as assessed in vitro, has demonstrated that FBL-reactive CD4' Th,
but not CD8+ CTL, utilize a chloroquine-sensitive antigen-processing pathway (18).
Thus, therapeutically effective FBL-reactive CTL and Th may recognize distinct
FBL-derived peptides generated from separate metabolic pathways . Since the na-
ture of the peptide may help determine which subset is activated, in this study, the
antigenic determinants recognized by FBL-reactive CD8' and CD4+ T cells were
evaluated .
The major retroviral proteins expressed by FBL are products of the envelope (env)
and gag genes of the helper Friend murine leukemia virus (FMuLV) (19-21) . Previous
studies using purified viral protein have shown that FBL-reactive Th recognize the
F-MuLV env-encoded glycoprotein gp70 (22) . However, characterization of FBL-
reactive CTL specificity has been more difficult, since CTL, unlike Th, require that
antigen be endogenously produced and presented in association with class IMHC
molecules rather than provided in soluble form for presentation byAPC . Therefore,
for this analysis, we have utilized rat fibroblast cells cotransfected with plasmids con-
taining FMuLV gag or env genes and the class I Db gene, since immunogenetic
studies have demonstrated restriction of FBL-specific CTL to the Db allele (23, 24) .
The results demonstrate that in the Friend retrovirus-induced tumormodel in which
tumor rejection can be mediated by either CTL or Th, antigens derived from dis-
crete retroviral proteins are responsible for activation of each T cell subset .
Materials and Methods
Mice .
￿
Female C57BL/6 (B6) H-2b mice and CBA/J H-2F mice were obtained from The
Jackson Laboratories, Bar Harbor, ME .
Cell Lines and Viruses .
￿
FBL is a Friend virus-induced erythroleukemia of B6 origin that
expresses FMuLV env- and gag-encoded determinants (19-21) . The transfectant fibroblast
cell lines expressing the class I-restricting antigen Db and/or Friend retrovirus proteins were
established as previously described (24) . Briefly, plasmids containing the Db gene and the
selectable marker pSV2neo were transfected into Fisher rat embryo fibroblasts (FRE) cells,
cultured with 400 hg/ml G418 (gentimycin sulfate ; Gibco Laboratories, Grand Island, NY),
and stable G418-resistant transfectants were isolated (cell line B2) . Plasmids consisting of
the F-MuLV provirus (pFMuLV ;7), orFMuLV gag or FMuLV env genes were constructed
as previously described (24), and cotransfected into FR.E cells along with Db in pSV2neo .
Stable G418-resistant cell lines were isolated that express Db plus F-MuLV, F-MuLV gag,
or FMuLV env, and termed FB2, Ps6, and N34, respectively.
Recombinant vaccinia virus containing the FMuLV env (vac-env) gene was constructedKLARNET ET AL
￿
459
and characterized previously, and kindly provided by Dr. Bernard Moss (NIAID, Bethesda,
MD) (25).
Immuno,fluorescence ofRat Fibroblast Transfectant Cell Lines.
￿
The rat fibroblast (FRE) cell lines
transfected with the viralexpression vectors described above were briefly trypsinized, washed,
and resuspended in HBSS with 0.17o NaN3 . 106 cells were incubated on ice for 30 min with
either FMuLV gp70'""-specific (hybridoma 350) or p159'9-specific (hybridoma 256) mAb
(kind gifts of Dr. Bruce Chesebro, Rocky Mountain Laboratory, Hamilton, MN) (26). The
cells were then centrifuged, washed twice with HBSS, and resuspended in 100 ,1 of a 1 :25
dilution of FITC-conjugated goat anti-mouse Ig serum (Tago Inc., Burlington, CA) . After
30 min at 0°C, cells were centrifuged, washed, and resuspended in HBSS with 5 17c BSA and
examined for membrane fluorescence.
Lymphocyte Cultures.
￿
Spleen cells from B6 mice inoculated intraperitoneally with three doses
of 2 x 10' irradiated FBL tumor cells (B6aFBL) at 2-wk intervals, with recombinant vaccinia
FMuLV envelope (B6«va-e-) virus or with recombinant vaccinia influenza hemagglutinin
(B6a,a-fl") virus (10' plaque-forming units, via tail scratch) were obtained at least 6 wk after
in vivo sensitization for in vitro assays. Cytolytic reactivitywas assessed after in vitro sensiti-
zation ofthese responder cells in MLC . 6 x 106 responder spleen cells were cultured for 5 d
in 24-well tissue culture plates (Costar, Cambridge, MA) in supplemented RPMI 1640 medium
containing 10% FCS, and stimulated with either 1.5 x 106 autologous uninfected spleno-
cytes, 1.5 x 106 splenocytes infected with recombinant vaccinia FMuLV envelope virus (mul-
tiplicity of infection, 10 :1) or 1.5 x 106 irradiated allogeneic stimulator cells, or 0.3 x 106
irradiated FBL.
Proliferative responses of FBL- and vaccinia (FMuLV)-envelope recombinant virus (vac-
eno)-primed T cell subsets were evaluated as previously described (27). Briefly, immune spleen
cells were RBC lysed and either alyt-2 .2 (hybridoma HO-2.2 from American Type Culture
Collection, Rockville, MD) plus C treated (denoted CD4' T cells) or aL3T4 (hybridoma
GK-1.5, a kind gift of Dr. Frank Fitch, University of Chicago) plus arat K (hybridoma Mar
18.5, a kind gift Dr. Lewis Lanier of Becton Dickinson & Co., Mountain View, CA) plus
C treated (denoted CD8' T cells), and then reconstituted to viable cell number. The effec-
tiveness and specificity of antibody plus C treatment in depleting the appropriate T cell sub-
population was assessed by binding of fluoresceinated antibodies to the CD4 and CD8 mole-
cules as previously described (28) . 8 x 105 responder T cells were incubated with either
8 x 104 irradiated (FBL), (10,000 rad) tumor cells or 4 x 105 irradiated (B6)x (2,500 rad)
spleen cells for 6 d. [3H]Thymidine, 1.0 gCi/well, was added for the final 24 h of incubation.
T Cell Clones.
￿
FBL-specific CD8'/CD4- (2.H8) and CD4'/CD8- (B10 and C8, kind gifts
of Dr. Michael Bookman, Medical Branch, NCI, NIH) T cell clones were established from
FBL-specific T cell lines generated from draining lymph nodes of B6 mice immunized with
irradiated (FBL), in CFA as previously described (8, 22, 29, 30). Proliferative assays were
performed in 96-well plates with 2 x 104 T cell clones/well, 5 x 105 irradiated syngeneic
(B6),/well, and with or without 2 x 104 irradiated FBL stimulator cells (10,000 rad). Prolifer-
ation was assessed after 3 d by the incorporation of [3H]thymidine (1.0 ACi/well) added
during the final 18 h of culture. Cytolytic reactivity was determined after culture of 5 x 105
T cell clones/well (24-well tissue culture plate, Costar, Cambridge, MA) with 5 x 106 irradi-
ated (B6)x and 2 x 105 irradiated (FBL), for 2 d.
Cytotoxicity Assay.
￿
Cytolytic activity was determined, as previously described (7, 8), by
a 4-6-h incubation of effector cells with 5 x 103 "Cr-labeled FBL tumor targets, transfected
fibroblast targets, or EL4 tumor cells (an antigenically distinct noncrossreacting tumor of
B6 origin) infected with either vaccinia or influenza (multiplicity of infection of 10:1). The
data shown are the means of triplicate determinations with spontaneous release values <25%.
Results
Expression of Cloned F-MuLVgag andenv Gene Products in TransfectedRat Fibroblast(FRE)
Cells. Before assessing the cytolytic reactivity of FBL-specific T cells to the trans-
fected FRE lines, expression of the viral antigens was defined by immunofluores-
cence (datanot shown). FRE cells transfected with the FMuLVprovirus (FB2) reacted460
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TABLE I
Recognition ofF-MuLV GAG-encoded Determinants by FBL-reactive Tc
' Spleen cells from B6 (H-2n) mice previously primed in vivo with irradiated FBL (B6avRL)
or unprimed B6 or CBA/J (H-2k) spleen cells were cultured for 5 d with irradiated (FBL)x
(10,000 rad) tumor cells or irradiated (B6), (3,000 rad) spleen cells as indicated . Effector
cells were harvested after 5 d and tested in a 4-h Cr-release assay at an 100 :1 E/T ratio with
labeled tumor or transfected fibroblast lines .
, Target cell lines used for analysis consisted of the Friend virus-induced tumor, FBL, or rat
fibroblasts transfected with the class I-restricting element Db alone (B2), D b and F-MuLV
(FB2), Db and the gag region of F-MuLV (Ps6), or Db and the env region of F-MuLV (N34) .
with both FMuLV anti-gp70e""-specific mAb as well as FMuLV pl5gag-specific
mAb . The gag-expressing FRE line (Ps6) bound anti-pl5gag but failed to react with
anti-gp70e"v, while the env-expressing rat fibroblast line (N34) bound anti-gp70env
but did not react with anti-pl5gag . FRE cells transfected with the class I-restricting
molecule D° alone (B2), however, were negative for staining with both anti-gp70e"v
and anti-P159'9 .
Recognition ofF-MuLV Antigenic Determinants by FBL-reactive CTL.
￿
To assess the
specificity of FBL-reactive CTL, responder FBL-primed B6 (H-26
) spleen cells, or
as controls, unprimed B6 or CBA/J (H-2~) spleen cells, were stimulated for 5 d with
either irradiated FBL or B6 splenocytes in vitro, and lytic activity assessed in a 6-h
"Cr-release assay against either FBL tumor cells or FRE lines transfected with D b
plus the full-length FMuLV genome, Db plus the FMuLV gag gene, D b plus the
FMuLV env gene, or Db alone (Table I) . All targets were lysed by the CBA/J al-
loreactive CTL specific for H-2° , insuring that the class I-restricting element Db
was adequately expressed on all targets . Target cells expressing FMuLV gag plus
the class I-restricting element Db (FBL, FB2, Ps6) were susceptible to lysis by FBL-
specific CTL, but only background lysis by FBL-specific CTL was observed with
the FRE lines transfected with either D° alone (B2) orFMuLV env plus D° (N34) .
Unprimed B6 splenocytes did not lyse any of the targets tested, confirming that in
vivo priming is required for in vitro generation of FBL-reactive cytotoxicity (31) .
Thus, FMuLV gag gene-encoded antigens were recognized by FBL-reactive CTL,
but CTL specific for env products could not be detected in significant numbers in
populations of FBL-reactive CTL effectors .
F-MuLV Env Transfectant Fibroblast Cells Express an Immunologically Functional Env
Product. The failure to detect in the above analysisFMuLV env-specificCTL could
potentially have resulted from the inability of the env-expressing transfectant line
(N34) to produce immunologically active env proteins rather than a lack of env-
specific CTL . Since previous studies (22) have suggested that FBL-specific CD4+
Target
cells , Components
Percent
from
FBL specific
([B6aFBLJ[FBLJx)
specific lysis of target
effector populations"
Allospecific
([CBAJ[B6J x )
cells
Unprimed
([B6][FBLJ .)
FBL F env + F gaglKb1V 80 78 3
B2 Db only 2 49 5
FB2 F env + F gag Db 34 25 1
Ps6 F gag,& 29 24 2
N34 F env,& 6 25 1KLARNET ET AL
TABLE II
F-MuLV Envelope Transfectant Fibroblast Cell Line Expresses
Immunologically Functional Gene Products
* 2 x 104 FBL-reactive CD4` (1310 and C8) or CD8` (2.H8) T cell clones were
stimulated with or without 2 x 104 irradiated (FBL),, (132),x, (Ps6), or (N34).
(10,000 rad), and 5 x 105 irradiated (B6)x (3,000 rad). IL-2 (10 U/ml) was
added to cultures containing 2 . H8 responder cells. Proliferation was assessed
after 3 d by the incorporation of [3H]thymidine (1.0 gCi/well) added during
the final 18 h of culture . Data presented represents the difference between the
mean values of triplicate determinants ofcultures stimulated with antigen or
with (B6)x cells.
l The stimulator cell lines used for analysis are described in Table I.
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T cells recognize gp70, the ability ofFBL-specific CD4+ T cell clones to proliferate
in response to FBL tumor cells and to the transfected fibroblast lines was examined
as an indicator for immunogenic env expression (Table II). The FBL-specific
CD4+/CD8 - T cell clones C8 and B10 proliferated to FBL and the fibroblast line
expressing gp70e°" (N34), but not to the line expressing Db alone (132) or the gag-
transfected line (Ps6). The response ofa CD8+/CD4- T cell clone, denoted 2.H8,
was alsoexamined, and, consistent with the specificityofthe FBL-reactive nonclonal
CD8+ population to FMuLV gag, this clone proliferated in response to gag-
expressing FBL and Ps6, but not B2 or N34. Thus, the inability to detect FMuLV
env-specific CTL was notdue to expression ofadefective FMuLVenv gene product
bytheenv-transfected fibroblast cell line. Moreover, these results, in conjunctionwith
previous reports analyzing the antigen specificity of FBL-reactive Th clones (22,
29), suggest that priming B6 mice with FBL induces predominantly or exclusively
Th responses specific for products of the env gene.
Cytolytic Reactivity after In Vivo Priming with Recombinant Vaccinia F-MuLV Env
Virus. Ourinability to detect FMuLV env-specific CTL seemed surprising, since
env-specific CTL have been demonstrated to other retrovirus-induced tumors (24,
32), and the FMuLV env gene products are expressed in an immunogenic fashion
by the transfected FRE cell lines (Table II). The lack ofreactivity in our system
could potentially result from the FBL tumor cell inappropriately processing the F
MuLV env gene product via the endogenous pathway for presentation with class I
molecules. Therefore, an alternativemechanism for expressingtheenv genein a fashion
known to induce CTL was explored. A recombinant vaccinia FMuLV virus was
utilized, because previous studies have demonstrated that viral genes incorporated
into vaccinia virus can serve as targets for antigen-specific CTL. Moreover, in vivo
immunization with recombinant vaccinia viruses has been shown to induce CTL
specific for products of the inserted gene (33).
B6 mice were primed in vivo either with FBL or vac-env virus, and the specificity
Stimulatorl Components
CD4'/CD8-
1310
Acpm *
C8
CD8'/CD4-
2.H8
FBL F env + F gag 47,631 37,271 29,803
132 None -387 210 - 1,585
Ps6 F gag 786 567 36,829
N34 F env 49,173 48,924 -417462
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TABLE III
Priming B6 Mice with Recombinant Vaccinia F-MuLV ENV Fails to Induce ENV-specific Tc
* Effector cells were harvested after 5 d and tested in a 4-6-h Cr-release assay at an 80:1 E/T ratio with
labeled FBL, EL-4, vac-infected EL-4 (10:1), or transfected fibroblast lines as detailed in Table 1 .
$ Spleen cells from B6 mice were immunized with irradiated FBL (B6gFBL), live vaccinia F-MuLV env recom-
binant (1160,--e); or left unprimed (116). Responder splenocytes were cultured with irradiated stimulator
(FBL),, (116) or vac-env-infected (multiplicity of 5:1) syngeneic B6 spleen cells, as indicated.
of the cytolytic Tcell response was assessed after in vitro stimulation with either
FBL orvac-env-infected syngeneicB6splenocytes. Therecombinant vacciniaenv virus
used for these studies has been shown to induce expression ofboth the gp85 env
precursor protein and the processed gp70 and p15E expressed by FBL (25). As pre-
viously observed, CTL generated by immunization to FBLrecognized FBLand the
Db- plus gag-expressing transfectant, but not the transfectant expressing env plus
Db or Db alone (Table III). The effector T cells from mice primed with vac-env did
not contain detectable CTL that lysed either the env-expressing transfected line or
the FBLtumor. This primingdid induce CTL, since stimulation ofvac-env-primed
splenocytes with vaccinia-infected stimulator cells induced effector cells that lysed
vaccinia-infected target cells (Table III). Thus, priming B6 mice with env antigens
inthecontext ofarecombinantvaccinia virus still failed to induce env-specificCTL.
Primingwith Vac-Env Induces CD4' ClassII-restricted TCellResponses.
￿
The inability
to detect FMuLV env-specific CTLafterpriming withvac-env could reflectinefficient
expression in vivo ofthe inserted gene encoding FMuLV env, resulting in failure
to induce env-specific T cell responses. Therefore, to determine if the env-encoded
gene productwasexpressedin a potentially immunogenicform during vac-envpriming,
the proliferative response of vac-env and FBL-primed CD4+ and CD8+ T cell
subsets tothe F-MuLV env-expressing tumorcell FBLwas assessed (Fig. 1). Purified
class II-restricted CD4' T cells, from both FBL and vac-env-primed B6 mice pro-
liferated in response to FBL, demonstrating that both immunogensprimed FBL-spe-
cific class II-restricted T cells. By contrast, purified CD8+ splenocytes from FBL-
primed butnot vac-env-primed mice proliferated in response to FBL, consistent with
the observed inability of class I-restricted T cells with cytolytic function to recog-
nize FMuLV env antigens. Moreover, the purified CD8+ T cell population from
vac-env-primed mice exhibited a class I-restricted proliferative alloresponse to B6b,1
class I mutant stimulator cells, demonstrating that immunization with vac-env did
not interfere with expression ofCD8+ proliferative responses. These results dem-
onstrate thatenv-encoded gene products areexpressedduring in vivo immunization
with FBLorvac-envrecombinantvirus, but envantigens effectively primeonly FBL-
specific CD4' T cells and not CD8+ T cells.
MLC$
Responder Stimulator
FBL
(F envlgaglKbDb)
Percent specific
B2 N34
(D) (F envIDb)
lysis of targets*
Ps6 EL-4
(F gaglDb) (KbDb)
EL-4/vac
(vac + KbDb)
B6aFBL (FBL), 78 3 2 25 1 2
vac-env 5 6 1 0 3 2
B6avac-env (FBL), 5 4 0 0 6 7
vac-env 4 3 1 0 4 59
B6 (FBL), 8 7 0 0 2 3
vac 3 2 0 0 2 7
BALB/c (136), 52 44 29 25 60 66KLARNET ET AL
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F[GURE 1.
￿
Ability of CD4' or CD8' T cells primed in vivo with vac-env or FBL tumor cells
to proliferate in vitro in response to (FBL)  . Spleen cells from unprimed B6 mice (B6) or mice
primed with irradiated FBL (B6~FBL) or live vaccinia F-MuLV env recombinant (B6«v;_  .) virus
were purified into CD8' or CD4' T cell subsets as described in Materials and Methods . 8 x
10' responder cells/well were cultured with 8 x 10' (FBL), tumor cells or 4 x 10 5 (B6) x spleen
cells for 5 d, and 1 .0 juCi/well [sH]thymidine was added during the final 24 h of culture . Data
presented were calculated as described in Table 1 .
Discussion
The data presented in this study show that FBL-reactive T cell subsets predomi-
nantly recognize tumor antigens derived from discrete retroviral proteins, with FBL-
reactive CD8+ CTL specific for FMuLV gag-encoded determinants and FBL-re-
active CD4' Th specific for FMuLV env-encoded determinants . This failure of
immunization with FBL to induce F-MuLU env-specific CD8+ T cells might result
from : (a)FBL processing env antigens poorly viathe endogenous pathway and failing
to present env in the context ofclass I molecules ; an hypothesis supported by recent
data demonstrating that different APCs, such as B cells, macrophages, and fibro-
blasts, process antigens differently and may present different epitopes (34) ; (b) env
antigens being unable to interact with H-2b class I molecules ; or (c) the B6 mouse
strain being a genetic nonresponder to the Friend env protein presented with H-2b
class I molecules .
To address the issue of the adequacy of presentation of env antigens by FBL, an
infectious recombinantvaccinia FMuLV env virus was utilized as an alternative mech-
anism for endogenously expressing and presenting the FMuLV env gene . Effector
T cells from mice primed with vac-env, as observed with FBL-reactive CTL, failed
to lyse either FBL tumor cells or the env-expressing transfectant cell line, despite
the fact that primingwith vac-env inducedimmunogenicexpression of env antigens .
Therefore, the failure to generate env-specificCTLcannot be due toaunique tumor-
associated env-processing defect in the transformed FBL tumor, since this defect
would also need to be present in cells infected with the recombinant vaccinia env
virus and/or the transfected fibroblast line .
An alternative explanation for the failure of FBL to induce env-specific CTL is
that env-encoded gene products are unable to bind to the H-2b class I molecules .
This is not true for all retroviral env products, since env-specific CTL can be de-
tected in B6 mice in response to Gross MuLU (32). Moreover, one of us (F Lilly)
has previously shown that BALB.B mice, which areH-2congenic to B6, can generate464
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FMuLVenv-specific CTL(24) . Thus, the failure to detectFMuLV env-specific CTL
is unlikely, due to the inability of retroviral env products to react with B6 class I
molecules. These data suggest that non-MHC genes can regulate the responses of
CD8' T cells to retrovirally encoded products, as has been shown for regulation
ofT cell responses to other proteins (35, 36), and that such background genes are
responsible for the nonresponder status ofB6 mice in regard to class I-restricted
response to FMuLV env . This cannot represent global tolerance to env proteins,
since B6 mice generate an env-specific CD4+ T cell response . While the mecha-
nisms) bywhich relatively largecomplex proteins, such as FMuLVgag and env-en-
coded gene products, uniquely activate separateT cell subsetsremain to be defined,
these data imply that, even in the setting in which human tumors are found to ex-
press unique tumorantigens capableofinducing aT cell response, host factors such
asMHC andnon-MHC genes may significantly influence an individual's ability to
generate tumor-specific CD4+ or CD8' T cell responses, and may determine which
effector population is most efficient at eradicating the tumor .
In addition to the role ofT cells in tumor rejection, the host T cell response to
viruses is critical for protection from viral diseases . For example, the generation
of viral-specific CTL has been shown to correlate with protection from a wide va-
riety of murine and human viruses, and may be important in protection from hu-
man retrovirus-related diseases (37-40) . The results ofthis current study, whichhas
shown that the major retroviral proteins may induce selectively only CD8' CTL
or CD4+ Th immune responses in the host, suggests that retroviral subunit vac-
cines may uniquely or predominantly activate only oneT cell subset in some indi-
viduals, and thus, may not provide the population with adequate protection against
viral infection . Preliminary studies evaluating the responses of chimpanzees vacci-
nated with arecombinant vaccinia virus containing theHIV env gene may illustrate
this concept, since class II-restricted T cells and neutralizing antibody responses
but no class I-restricted CTL were detected, and the chimps were not protected
from challenge with HIV (40) . Consistent with our findings that class I-restricted
FBL-specific CTL can recognize gag-encoded determinants, recent reports have
demonstrated HIVspecificCTLthat recognize gagproteins (41), and such responses
may be particularly important to individuals not able to generate class I-restricted
env-specific T cell responses . Further studies, using similar approaches to analyze
the immunogenetics of responses to distinct retroviral and/or tumor antigens, may
provide important insights into the requirements for eliciting protective host responses
to infectious retroviruses and transformed cells .
Summary
Immunization ofC57BL/6 (B6) mice with FBL, a Friend murine leukemia virus
(FMuLV), induces both tumor-specific cytolytic CD8' (CTL) and lymphokine-
producing CD4 ` Th that are effective in adoptive therapy ofB6 mice bearing dis-
seminated FBL leukemia . The current study evaluated the FMuLV antigenic de-
terminants expressed on FBL that are recognized by FBL-reactive C138' and CD4'
T cells . To identify the specificity of the FBL-reactive CD8' CTL, Fisher rat em-
bryo fibroblast (FRE) cells transfected with plasmids encoding FMuLVgag or enve-
lope (env) gene products plus the class I-restricting element Db were utilized . FBL-
reactive CTL recognized FRE target cells transfected with theFMuLVgag-encodedKLARNET ET AL
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gene products, but failed to recognize targets expressing FMuLV env. Attempts
to generate env-specific CD8' CTL by immunization with a recombinant vaccinia
virus containing an inserted FMuLV env gene were unsuccessful, despite the gener-
ation ofa cytolytic response to vaccinia epitopes, implying that B6 mice fail to generate
CD8+ CTL to env determinants. By contrast, CD4' Th clones recognized FRE
target cells transfected with env and not gag genes, and immunization with the recom-
binant vaccinia virus induced an env-specific CD4 + T cell response. These data
show that in a Friend retrovirus-induced tumor model in which tumor rejection
can be mediated by either CTL or Th, antigens derived from discrete retroviral pro-
teins are predominantly responsible for activation of each T cell subset.
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